Kisqali

Oncology

Indications and Usage

Early Breast Cancer

KISQALI is indicated in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence.

Advanced or Metastatic Breast Cancer

KISQALI is indicated for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with:

an aromatase inhibitor as initial endocrine-based therapy; or
fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy.

More than 200,000 clinicians have integrated PrescriberPoint into their clinical workflows

HOW IT WORKS

The easy way to access samples

Create Free AccountRequest, track, and manage samples from multiple brands

Connect with a RepHave access to pharma representatives in one place to request your samples

Get your SampleManage your reps and samples in one place

WHO IS PRESCRIBERPOINT

Increasing patient access to medications they need

At PrescriberPoint, we're revolutionizing how healthcare providers get patients the medications they need. We craft solutions that help providers address the challenges in patient access and improve outcomes.

200K+Visitors Each Month

100K+Engagements Each Month

1M+Resources Viewed

WHAT HCPS ARE SAYING

FAQs

All you need to know to order samples

Currently, PrescriberPoint is available only in the U.S, but we are excited to expand our reach in the future! Stay connected by following us or signing up for our newsletter to get the latest updates, including announcements about new market launches.